NextCure (NXTC) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NextCure (NXTC) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 1.0% versus a loss of 88.4%. Over five years, NXTC leads with a -93.5% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($30.4 million vs $30.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NXTC | RNAZ |
|---|---|---|
| Share price | $6.63 | $1.79 |
| Market cap | $30.33M | $30.36M |
| 1-day change | -2.29% | +4.81% |
| YTD return | -52.22% | -74.96% |
| 1-year return | -1.02% | -88.45% |
| 5-year return | -93.53% | -100.00% |
| EPS (TTM) | $-8.71 | $-52.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $15.94 |
| 52-week low | $1.55 | $1.52 |
| Distance from 52-week high | -57.91% | -88.75% |
| Analyst consensus | none | — |
| Avg. price target upside | +201.89% | — |
| Average volume | 2.11M | 50.19K |
| Shares outstanding | 4.58M | 16.93M |
| Employees | 40 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed RNAZ by 87.4 percentage points over the past year.
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
NXTC vs RNAZ FAQ
Which is bigger, NextCure or TransCode Therapeutics?
TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $30.36M compared with $30.33M for NextCure (NXTC).
Which stock has performed better over the past year, NXTC or RNAZ?
NXTC returned -1.02% over the past 12 months, compared with -88.45% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are NextCure and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.